Synopsis
Synopsis
0
USDMF
0
JDMF
0
EU WC
0
KDMF
0
FDF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 25-cyclohexyl-25-de(1-methylpropyl)-5-deoxy-22 23-dihydro-5-(hydroxyimino)-avermectin B1 Monosaccharide
1. Revolution
2. 220119-17-5
3. Uk-124,114
4. 165108-07-6
5. Uk-124114
6. A2669owx9n
7. Unii-a2669owx9n
8. Stronghold
9. (1r,4s,5's,6r,6's,8r,10e,12s,13s,14e,16e,20r,21z,24s)-6'-cyclohexyl-24-hydroxy-21-hydroxyimino-12-[(2r,4s,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
10. Ncgc00095066-01
11. 25-cyclohexyl-25-de(1-methylpropyl)-5-deoxy-22 23-dihydro-5-(hydroxyimino)-avermectin B1 Monosaccharide
12. Revolution (antibiotic)
13. Selamectin [mi]
14. Selamectin [inn]
15. Selamectin (usan/inn)
16. Selamectin [usan]
17. Selamectin [mart.]
18. Dsstox_cid_25903
19. Dsstox_rid_81215
20. Selamectin [usp-rs]
21. Dsstox_gsid_45903
22. Schembl120105
23. Selamectin [usan:inn:ban]
24. Selamectin [green Book]
25. Chembl1908325
26. Dtxsid6045903
27. Chebi:177562
28. Selamectin [usp Monograph]
29. Ex-a3581
30. Tox21_111408
31. Mfcd31621085
32. Zinc85537134
33. Stronghold Component Selamectin
34. Akos026749796
35. Cs-7778
36. Db11459
37. Nsc 758615
38. Selamectin [ema Epar Veterinary]
39. Selamectin Component Of Stronghold
40. (2ae,4e,5's,6s,6's,7s,8e,11r,13r,15s,17ar,20ar,20bs)-6'-cyclohexyl-7-((2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)oxy)-3',4',5',6,6',7,10,11,14,15,20a,20b-dodecahydro-20b-hydroxy-5',6,8,19-tetramethylspiro(11,15-methano-2h,13h,17h-furo(4,3,2-pq)(2,6)benzodioxacyclooctadecin-13,2'-(2h)pyran)-17,20(17ah)-dione 20-oxime
41. 25-cyclohexyl-4'-o-de(2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-avermectin A1a
42. Avermectin A1a, 25-cyclohexyl-4'-o-de(2,6-dideoxy-3-o-methyl-.alpha.-l-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-
43. Selamectin 100 Microg/ml In Acetonitrile
44. Stronghold Plus Component Selamectin
45. Hy-107212
46. Uk 124114
47. Cas-165108-07-6
48. Selamectin Component Of Stronghold Plus
49. D05813
50. J-014423
51. Avermectin A1a, 25-cyclohexyl-4'-o-de(2,6-dideoxy-3-o-methyl-.alpha.-l-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5(hydroxyimino)-, (5z)-
52. Avermectin A1a, 25-cyclohexyl-4'-o-de(2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-(hydroxyimino)-, (5z)-
Molecular Weight | 770.0 g/mol |
---|---|
Molecular Formula | C43H63NO11 |
XLogP3 | 5.4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 4 |
Exact Mass | 769.44011183 g/mol |
Monoisotopic Mass | 769.44011183 g/mol |
Topological Polar Surface Area | 155 Ų |
Heavy Atom Count | 55 |
Formal Charge | 0 |
Complexity | 1550 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 14 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 4 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
- Treatment and prevention of flea infestations caused by Ctenocephalides spp. for one month following a single administration. This is as a result of the adulticidal, larvicidal and ovicidal properties of the product. The product is ovicidal for 3 weeks after administration. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter up to seven week of age. The product can be used as part of a treatment strategy for flea allergy dermatitis and through its ovicidal and larvicidal action may aid in the control of existing environmental flea infestations in area to which the animal has access.
- Prevention of heartworm disease caused by Dirofilaria immitis with monthly administration. The product may be safely administered to animals infected with adult heartworms, however, it is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more living in countries where a vector exists should be tested for existing adult heartworm infections before beginning medication with the product. It is also recommended that dogs should be tested periodically for adult heartworm infections, as an integral part of a heartworm prevention strategy, even when the product has been administered monthly. This product is not effective against adult D. immitis.
- Treatment of ear mites (Otodectes cynotis).
Cats:
- Treatment of biting lice infestations (Felicola subrostratus)
- Treatment of adult roundworms (Toxocara cati)
- Treatment of adult intestinal hookworms (Ancylostoma tubaeforme).
Dogs:
- Treatment of biting lice infestations (Trichodectes canis)
- Treatment of sarcoptic mange (caused by Sarcoptes scabiei)
- Treatment of adult intestinal roundworms (Toxocara canis).
* Cats and dogs: :
* Treatment and prevention of flea infestations: caused by Ctenocephalides spp. for one month following a single administration. This is as a result of the adulticidal, larvicidal and ovicidal properties of the product. The product is ovicidal for 3 weeks after administration. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter up to seven weeks of age. The product can be used as part of a treatment strategy for flea allergy dermatitis and through its ovicidal and larvicidal action may aid in the control of existing environmental flea infestations in areas to which the animal has access.
* Prevention of heartworm disease: caused by Dirofilaria immitis with monthly administration.
The product may be safely administered to animals infected with adult heartworms, however, it is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more living in countries where a vector exists should be tested for existing adult heartworm infections before beginning medication with the product. It is also recommended that dogs should be tested periodically for adult heartworm infections, as an integral part of a heartworm prevention strategy, even when the product has been administered monthly. This product is not effective against adult D. immitis.
* Treatment of ear mites: (Otodectes cynotis).
* Cats: :
- Treatment of biting lice infestations (Felicola subrostratus)
- Treatment of adult roundworms (Toxocara cati)
- Treatment of adult intestinal hookworms (Ancylostoma tubaeforme)
- Treatment of biting lice infestations (Trichodectes canis)
- Treatment of sarcoptic mange (caused by Sarcoptes scabiei)
* Cats and dogs: :
-
* Treatment and prevention of flea infestations: caused by Ctenocephalides spp. for one month following a single administration. This is as a result of the adulticidal, larvicidal and ovicidal properties of the product. The product is ovicidal for 3 weeks after administration. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter up to seven weeks of age. The product can be used as part of a treatment strategy for flea allergy dermatitis and through its ovicidal and larvicidal action may aid in the control of existing environmental flea infestations in areas to which the animal has access.
-
* Prevention of heartworm disease: caused by Dirofilaria immitis with monthly administration. Stronghold may be safely administered to animals infected with adult heartworms, however, it is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more living in countries where a vector exists should be tested for existing adult heartworm infections before beginning medication with Stronghold. It is also recommended that dogs should be tested periodically for adult heartworm infections, as an integral part of a heartworm prevention strategy, even when Stronghold has been administered monthly. This product is not effective against adult D. immitis.
-
* Treatment of ear mites: (Otodectes cynotis).
*:
* Cats: :
- Treatment of biting lice infestations (Felicola subrostratus
- Treatment of adult roundworms (Toxocaracati)
- Treatment of adult intestinal hookworms (Ancylostoma tubaeforme).
*:
* Dogs: :
- Treatment of biting lice infestations (Trichodectes canis)
- Treatment of sarcoptic mange (caused by Sarcoptes scabiei)
- Treatment of adult intestinal roundworms (Toxocara canis).
Antiparasitic Agents
Drugs used to treat or prevent parasitic infections. (See all compounds classified as Antiparasitic Agents.)
QP54AA05
QP54AA05
QP54AA05
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
VMF Number : 6176
Submission : 2017-01-05
Status : Active
Type : II
Certificate Number : CEP 2017-124 - Rev 01
Issue Date : 2024-02-23
Type : Chemical
Substance Number : 2268
Status : Valid
Certificate Number : CEP 2023-007 - Rev 00
Issue Date : 2024-04-18
Type : Chemical
Substance Number : 2268
Status : Valid
VMF Number : 6279
Submission : 2023-01-05
Status : Active
Type : II
Certificate Number : R1-CEP 2017-070 - Rev 00
Issue Date : 2023-05-02
Type : Chemical
Substance Number : 2268
Status : Valid
Certificate Number : R0-CEP 2018-272 - Rev 02
Issue Date : 2023-04-12
Type : Chemical
Substance Number : 2268
Status : Valid
NDC Package Code : 66603-702
Start Marketing Date : 2017-06-28
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
VMF Number : 6527
Submission : 2023-05-23
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Selamectin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Selamectin, including repackagers and relabelers. The FDA regulates Selamectin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Selamectin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Selamectin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Selamectin supplier is an individual or a company that provides Selamectin active pharmaceutical ingredient (API) or Selamectin finished formulations upon request. The Selamectin suppliers may include Selamectin API manufacturers, exporters, distributors and traders.
click here to find a list of Selamectin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Selamectin CEP of the European Pharmacopoeia monograph is often referred to as a Selamectin Certificate of Suitability (COS). The purpose of a Selamectin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Selamectin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Selamectin to their clients by showing that a Selamectin CEP has been issued for it. The manufacturer submits a Selamectin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Selamectin CEP holder for the record. Additionally, the data presented in the Selamectin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Selamectin DMF.
A Selamectin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Selamectin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Selamectin suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Selamectin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Selamectin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Selamectin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Selamectin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Selamectin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Selamectin suppliers with NDC on PharmaCompass.
Selamectin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Selamectin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Selamectin GMP manufacturer or Selamectin GMP API supplier for your needs.
A Selamectin CoA (Certificate of Analysis) is a formal document that attests to Selamectin's compliance with Selamectin specifications and serves as a tool for batch-level quality control.
Selamectin CoA mostly includes findings from lab analyses of a specific batch. For each Selamectin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Selamectin may be tested according to a variety of international standards, such as European Pharmacopoeia (Selamectin EP), Selamectin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Selamectin USP).
LOOKING FOR A SUPPLIER?